- Home
- PHVS vs TXO Comparison
PHVS vs TXO Comparison
Compare PHVS & TXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- TXO
- Stock Information
- Founded
- PHVS 2015
- TXO 2012
- Country
- PHVS Switzerland
- TXO United States
- Employees
- PHVS N/A
- TXO N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- TXO Oil & Gas Production
- Sector
- PHVS Health Care
- TXO Energy
- Exchange
- PHVS Nasdaq
- TXO Nasdaq
- Market Cap
- PHVS 909.5M
- TXO 788.6M
- IPO Year
- PHVS 2021
- TXO 2023
- Fundamental
- Price
- PHVS $17.99
- TXO $15.91
- Analyst Decision
- PHVS Buy
- TXO
- Analyst Count
- PHVS 6
- TXO 0
- Target Price
- PHVS $37.17
- TXO N/A
- AVG Volume (30 Days)
- PHVS 62.5K
- TXO 325.9K
- Earning Date
- PHVS 08-13-2025
- TXO 08-05-2025
- Dividend Yield
- PHVS N/A
- TXO 14.90%
- EPS Growth
- PHVS N/A
- TXO N/A
- EPS
- PHVS N/A
- TXO 0.40
- Revenue
- PHVS N/A
- TXO $299,696,000.00
- Revenue This Year
- PHVS N/A
- TXO $33.41
- Revenue Next Year
- PHVS N/A
- TXO $9.20
- P/E Ratio
- PHVS N/A
- TXO $39.44
- Revenue Growth
- PHVS N/A
- TXO 3.43
- 52 Week Low
- PHVS $11.51
- TXO $14.78
- 52 Week High
- PHVS $25.50
- TXO $22.39
- Technical
- Relative Strength Index (RSI)
- PHVS 58.65
- TXO 57.04
- Support Level
- PHVS $16.00
- TXO $15.15
- Resistance Level
- PHVS $17.53
- TXO $16.15
- Average True Range (ATR)
- PHVS 1.14
- TXO 0.37
- MACD
- PHVS 0.01
- TXO 0.17
- Stochastic Oscillator
- PHVS 59.77
- TXO 82.48
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.